Stay up to date with the latest news and events from the NIHR Manchester Biomedical Research Centre.
Professor Caroline Dive and Professor Chris Griffiths have been honoured by the Queen in the 2018 New Year’s Honours list.
Continue reading full article: Manchester BRC researchers named in New Year’s Honours List
Community screening for osteoporosis could prevent more than a quarter of hip fractures in older women – according to new research.
Continue reading full article: Screening could catch a quarter of hip fractures before they happen
This event in partnership with Manchester Precision Medicine Institute and Health Innovation Manchester will provide attendees with an understanding of precision medicine approaches and an overview of some of the existing research in this area across Manchester and within industry.
Continue reading full article: Event – How Precision Medicine will transform healthcare – 2 March 2018
Researchers set out to determine whether three of the recommended biologic therapies (etanercept, adalimumab or ustekinumab) for psoriasis elevate the risk of serious infection above that for non-biologic, conventional tablet treatments.
Continue reading full article: Researchers find no increased risk of serious infection when comparing biologic and non-biologic psoriasis treatments
Professor Gareth Evans, Cancer Lead for the Manchester Biomedical Research Centre (BRC) outlines why this NIHR funding is so important to being able to deliver a personalised approach to disease treatment and prevention.
Continue reading full article: Delivering a more personalised approach for the treatment and prevention of cancer
Supported by the NIHR Manchester BRC and CRF, the “Combat my Cough” event on 7 November 2017 at Wythenshawe hospital provided the opportunity to engage with patients and the public around cough research; through talks, workshops, advice sessions and activities.
Continue reading full article: Patients and public engage around cough research at ‘Combat my Cough’
In April, Manchester patients had access to twice as many cancer trials*, as a result of a new strategic partnership across five CRUK Experimental Cancer Medicine Centres (ECMCs). This figure is likely to further increase as a result of the TARGET trial.
Continue reading full article: Strategic partnership doubles cancer trials available to Manchester patients
Researchers across Manchester have pulled together to open phase two of the TARGET cancer trial, which is on track to recruit over 100 patients in its first year. This is a significant achievement in the wake of the fire at the Paterson Building in April.
Continue reading full article: Second phase of trial to match patients to the right cancer treatment now open